COCMM14/1OVERVIEW OF ACTIVITY To bridge the gap between research and patient care, this CME activity will use the perspectives of clinical investigators on key management challenges and controversies in the treatment of MM to assist medical oncologists, hematologists, hematologist-oncologists, hematology-oncology fellows and other cancer clinicians in the formulation of up-to-date and appropriate treatment strategies. LEARNING OBJECTIVES
ACCREDITATION STATEMENT CME credit is no longer available for this issue CREDIT DESIGNATION STATEMENT CME credit is no longer available for this issue HOW TO USE THIS CME ACTIVITY CME credit is no longer available for this issue CONTENT VALIDATION AND DISCLOSURES FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Andrzej J Jakubowiak, MD, PhD Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Sanofi, Skyline Pharmaceuticals Inc; Consulting Agreements and Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary. Ola Landgren, MD, PhD Contracted Research: Celgene Corporation, Onyx Pharmaceuticals, an Amgen subsidiary. Philip L McCarthy, MD Advisory Committee: Celgene Corporation, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Sanofi. Joseph Mikhael, MD, MEd Contracted Research: Celgene Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Sanofi. Philippe Moreau, MD Advisory Committee: Celgene Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals, an Amgen subsidiary, Sanofi. Antonio Palumbo, MD Advisory Committee and Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Sanofi. Noopur Raje, MD Consulting Agreements: Amgen Inc, Celgene Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals, an Amgen subsidiary. Paul G Richardson, MD Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation. EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc. RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose. This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors. This activity is supported by educational grants from Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation and Onyx Pharmaceuticals, an Amgen subsidiary. Hardware/Software Requirements: Last review date: December 2014 |